Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEM-iSMART Sub-protocol B: Dasatinib + Venetoclax in R/R ALL/LBL
NCT05751044Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2025
- Primary completion
- Feb 2032
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 14
01
Overview
A Phase 2 trial of dasatinib, venetoclax in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Princess Máxima Center for Pediatric Oncology. Started Oct 2025; status: recruiting.
02
Drugs
dasatinibvenetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT05751044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751044.